Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelotanserin for RBD in DLB or PDD
NCT02708186Phase 2Completed
- Sponsor
- Sio Gene Therapies
- Start
- Mar 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in REM sleep behavior disorder (RBD) comparing Nelotanserin with Placebo (2 arms). Primary endpoint: Change in the Frequency of REM Sleep Behavior Disorders (RBD) From Baseline to the End of the Treatment Period at 28 days. Started Mar 2016; status: completed.
02
Drugs
nelotanserin
03
Conditions
REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT02708186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708186.